HSBC Upgrades Thermo Fisher Scientific (NYSE:TMO) to Strong-Buy

Thermo Fisher Scientific (NYSE:TMO) was upgraded by equities researchers at HSBC from a “hold” rating to a “strong-buy” rating in a research report issued on Tuesday, Zacks reports.

A number of other research analysts have also issued reports on the company. Wolfe Research began coverage on Thermo Fisher Scientific in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $535.00 target price on the stock. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Evercore set a $570.00 target price on shares of Thermo Fisher Scientific in a research report on Monday, July 6th. Weiss Ratings raised shares of Thermo Fisher Scientific from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday. Finally, Morgan Stanley raised their price target on shares of Thermo Fisher Scientific from $620.00 to $650.00 and gave the company an “overweight” rating in a research note on Friday, July 24th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $619.41.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock opened at $600.32 on Tuesday. The firm has a market cap of $221.97 billion, a PE ratio of 32.29, a P/E/G ratio of 2.58 and a beta of 0.85. Thermo Fisher Scientific has a twelve month low of $435.27 and a twelve month high of $647.00. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. The business has a 50-day moving average price of $564.35 and a 200 day moving average price of $512.92.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. The company had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.Thermo Fisher Scientific’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Sell-side analysts predict that Thermo Fisher Scientific will post 25.13 earnings per share for the current fiscal year.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 275 shares of the company’s stock in a transaction on Monday, August 24th. The shares were sold at an average price of $627.05, for a total transaction of $172,438.75. Following the completion of the sale, the chief executive officer owned 123,925 shares of the company’s stock, valued at $77,707,171.25. This represents a 0.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa P. Britt sold 11,440 shares of the stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the completion of the sale, the vice president owned 14,784 shares of the company’s stock, valued at $9,064,366.08. This trade represents a 43.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 73,768 shares of company stock worth $44,122,820. Company insiders own 0.33% of the company’s stock.

Institutional Investors Weigh In On Thermo Fisher Scientific

Large investors have recently made changes to their positions in the stock. California State Teachers Retirement System lifted its position in Thermo Fisher Scientific by 49,331.5% during the second quarter. California State Teachers Retirement System now owns 282,654,735 shares of the medical research company’s stock worth $141,711,778,000 after buying an additional 282,082,924 shares in the last quarter. J. Stern & Co. LLP grew its holdings in Thermo Fisher Scientific by 58,006.4% in the 4th quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company’s stock valued at $18,258,082,000 after buying an additional 31,455,105 shares in the last quarter. BlackRock Inc. acquired a new stake in shares of Thermo Fisher Scientific in the 2nd quarter worth $15,501,867,000. Corient Private Wealth LP acquired a new position in shares of Thermo Fisher Scientific during the 2nd quarter valued at about $382,547,000. Finally, Norges Bank acquired a new stake in Thermo Fisher Scientific during the fourth quarter worth about $3,072,744,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.